Compile Data Set for Download or QSAR
Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 11087
TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322528(5-[3-[4-(3-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 0.400nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 0.5nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.600nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.800nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.800nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322528(5-[3-[4-(3-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 1nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 1.10nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1.40nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1.5nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322518(5-[3-(1H-benzimidazol-2-yl)chroman-6-yl]oxy-3,4-di...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322518(5-[3-(1H-benzimidazol-2-yl)chroman-6-yl]oxy-3,4-di...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322525(5-[3[4-(4-pyridyl)-1H-imidazol-2-yl]chroman-6-yl]o...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322525(5-[3[4-(4-pyridyl)-1H-imidazol-2-yl]chroman-6-yl]o...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322528(5-[3-[4-(3-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322528(5-[3-[4-(3-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322527(5-[3-(4-tert-butyl-1H-imidazol-2-yl)chroman-6-yl]o...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322538(5-[[3-(4-phenyl-1H-imidazol-2-yl)-2H-chromen-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322537(5-[3-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imid...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322540(5-[3-(5-phenyl-1H-pyrazol-3-yl)chroman-6-yl]oxy-3,...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322540(5-[3-(5-phenyl-1H-pyrazol-3-yl)chroman-6-yl]oxy-3,...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322542(5-[[(3R)-3-(4-phenyl-1H-imidazol-2-yl)-2,3-dihydro...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322542(5-[[(3R)-3-(4-phenyl-1H-imidazol-2-yl)-2,3-dihydro...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322541(5-[[(3S)-3-(4-phenyl-1H-imidazol-2-yl)-2,3-dihydro...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322541(5-[[(3S)-3-(4-phenyl-1H-imidazol-2-yl)-2,3-dihydro...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322530(5-[3-[5-(2-chlorophenyl)-1H-imidazol-2-yl]chroman-...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322530(5-[3-[5-(2-chlorophenyl)-1H-imidazol-2-yl]chroman-...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322529(5-[3-[4-(2-thienyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322532(5-[3-[4-(benzofuran-3-yl)-1H-imidazol-2-yl]chroman...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322532(5-[3-[4-(benzofuran-3-yl)-1H-imidazol-2-yl]chroman...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322531(5-[3-[5-(3-chlorophenyl)-1H-imidazol-2-yl]chroman-...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322531(5-[3-[5-(3-chlorophenyl)-1H-imidazol-2-yl]chroman-...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322533(5-[3-[5-(3-pyridyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322533(5-[3-[5-(3-pyridyl)-1H-imidazol-2-yl]chroman-6-yl]...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322536(5-[3-[5-(1,3-benzodioxol-5-yl)-1H-imidazol-2-yl]ch...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322536(5-[3-[5-(1,3-benzodioxol-5-yl)-1H-imidazol-2-yl]ch...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322535(5-[3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]chroman-...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322535(5-[3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]chroman-...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322519(5-[3-(7-chloro-1H-benzimidazol-2-yl]chroman-6-yl]o...)
Affinity DataIC50: 52nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322538(5-[[3-(4-phenyl-1H-imidazol-2-yl)-2H-chromen-6-yl]...)
Affinity DataIC50: 52nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322519(5-[3-(7-chloro-1H-benzimidazol-2-yl]chroman-6-yl]o...)
Affinity DataIC50: 52nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322537(5-[3-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imid...)
Affinity DataIC50: 52nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322539(5-[3-(3-phenyl-1,2,4-oxadiazol-5-yl)chroman-6-yl]o...)
Affinity DataIC50: 52nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: